Neuroblastoma

• Published in: Seminars in pediatric surgery Vol. 21; no. 1; pp. 2 - 14
• Main Author: Davidoff, Andrew M., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2012
• Subjects: Child; Child, Preschool; Clinical Trials as Topic - methods; Combined Modality Therapy; Humans; Immunotherapy; Infant; Neoplasm Recurrence, Local - etiology; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - surgery; Neoplasm Staging - classification; Neuroblastic tumors; Neuroblastoma; Neuroblastoma - etiology; Neuroblastoma - genetics; Neuroblastoma - pathology; Neuroblastoma - surgery; Pediatrics; Risk; Risk factors; Surgery; Targeted therapy; Neuroblastoma; Neuroblastic tumors; Targeted therapy; Immunotherapy; Risk factors
• ISSN: 1055-8586; 1532-9453
• DOI: 10.1053/j.sempedsurg.2011.10.009

Neuroblastoma is a heterogeneous disease; tumors can spontaneously regress or mature, or display an aggressive, therapy-resistant phenotype. Increasing evidence indicates that the biological and molecular features of neuroblastoma significantly influence and are highly predictive of clinical behavior. Because of this, neuroblastoma has served as a paradigm for biological risk assessment and treatment assignment. Most current clinical studies of neuroblastoma base therapy and its intensity on a risk stratification that takes into account both clinical and biological variables predictive of relapse. For example, surgery alone offers definitive therapy with excellent outcome for patients with low-risk disease, whereas patients at high risk for disease relapse are treated with intensive multimodality therapy. In this review recent advances in the understanding of the molecular genetic events involved in neuroblastoma pathogenesis are discussed, and how they are impacting the current risk stratification and providing potential targets for new therapeutic approaches for children with neuroblastoma. In addition, the results of significant recent clinical trials for the treatment of neuroblastoma are reviewed.